European CAR T-cell Meeting
At this years 8th European CAR T-cell Meeting, taking place from 12-14 February 2026, in Palma de Mallorca, Spain, we are proud to be sharing new data and engaging with the scientific community to drive progress in the care of people living with blood cancers.
You can see the scientific programme on the congress platform by clicking on the button below.
Below is a selection of the Gilead and Kite abstracts being presented at the 8th European CAR T-cell Meeting:
Global brexucabtagene autoleucel (brexu-cel) manufacturing experience for adult patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) or mantle cell lymphoma (MCL)
Real world, real lives: Navigating the RWE shaping CAR T care in R/R DLBCL
Join Dr Gloria Iacoboni and Dr Leyre Bento De Miguel as they examine CAR T efficacy and safety in broader patient populations outside of clinical trials, including the evolution of AE management with increasing CAR T experience. It will also address the impact of manufacturing on patient care, exploring the association between earlier treatment with CAR T and improved patient outcomes.
Friday 13 February, 16:50 – 17:35 CET
Palma Convention Centre, Palma de Mallorca, Spain
Add event to calendarAgenda
16:50 – 16:53 CET
Welcome and introduction
16:53 – 17:03 CET
Decoding the evidence: An approach to comparing RWE
17:03 – 17:13 CET
Building confidence with evidence: Real-world insights into CAR T management
17:13 – 17:18 CET
Panel discussion
17:18 – 17:28 CET
The speed advantage: Exploring how rapid and reliable manufacturing impacts patient care
17:28 – 17:33 CET
Audience Q&A
17:33 – 17:35 CET
Conclusion and closing remarks
MEET THE CHAIR
Dr Gloria Iacoboni
Gloria Iacoboni trained in Haematology at La Fe University Hospital in Valencia, Spain. After finishing her Haematology degree, she carried out a 1-year lymphoma fellowship at the Oncology Institute (IOSI) in Lugano, Switzerland (2016-2017).
She started working in 2017 at Vall d’Hebron University Hospital (Barcelona, Spain) as a Haematology Consultant focused on clinical trials for lymphoma. She joined the CAR T-cell Program in 2018 with the first clinical trials and, once approved, with the commercially-available CAR-T products. She is currently part of the Advances Therapies Unit and Lymphoma Unit of the Haematology Department, mainly focused on CAR T-cells, bispecific antibodies and other novel immunotherapy strategies for lymphoma patients.